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Garcinol, a polyisoprenylated benzophenone, is extracted from the rind of the fruit of Garcinia indica, a plant found extensively
in tropical regions. Although the fruit has been consumed traditionally over centuries, its biological activities, speciﬁcally its
anticancer potential is a result of recent scientiﬁc investigations. The anticarcinogenic properties of garcinol appear to be
moderated via its antioxidative, anti-inﬂammatory, antiangiogenic, and proapoptotic activities. In addition, garcinol displays
eﬀective epigenetic inﬂuence by inhibiting histone acetyltransferases (HAT 300) and by possible posttranscriptional modulation
by mi RNA proﬁles involved in carcinogenesis. In vitro as well as some in vivo studies have shown the potential of this compound
against several cancers types including breast, colon, pancreatic, and leukemia. Although this is a promising molecule in terms of
its anticancer properties, investigations in relevant animal models, and subsequent human trials are warranted in order to fully
appreciate and conﬁrm its chemopreventative and/or therapeutic potential.
1.Introduction
The extract from the fruit of Garcinia indica,p o p u l a r l y
known as Kokum or Mangosteen has been valued in the
Indiansubcontinent,Africa,andChinaforitssweetandsour
taste and has traditionally been used as a seasoning, a snack,
or steeped in syrup for a refreshing drink. In addition, it has
been recommended by the Ayurvedic system of medicine for
treatment of ailments such as heat strokes, infections, and
edema [1].
The major chemical constituents of the fruit extract
include citric acid, hydroxycitric acid (HCA), hydroxycitric
acidlactone,andoxalicacidinadditiontothebenzophenone
derivatives, garcinol, and its isomer isogarcinol [1]. Of these,
HCA has shown hypocholesterolemic and antiobesity activ-
ity, while the benzophenone derivatives have been associated
more closely with antioxidant behavior. In this paper, we
will concentrate on the biological properties of garcinol
with a speciﬁc focus on its anticarcinogenic capabilities.
Figure 2 gives an overview of the mechanistic insight into the
anticancer activity of garcinol.
2. Chemical Properties of Garcinol
Garcinol (C38H50O6; molecular weight 602), a yellow crys-
talline compound, with a melting point of 132◦Ci ss t r u c -
turally similar to curcumin, an established antioxidant, anti-
aging, and anticarcinogenic agent, by virtue of containing
both phenolic hydroxyl groups and the β-diketone moiety
[2].
The chemical structure of garcinol, also known as Cam-
boginol (Figure 1), was elucidated by Rao and coworkers
in 1980 using proton NMR and IR spectroscopy where
they determined the location of a terminal alkene as well
as the presence of a β-diketone from the compound’s
ability to enolize [2]. The terminal alkene contained in an
unsaturated isoproprenyl substituent of the molecule can
undergo cyclization under acidic conditions to produce iso-
gracinol [3]. The latter, oxidized isomer of garcinol has also
been associated with antitumorigenic, antiobesity, antiulcer,
antibacterial, antiviral, and anti-inﬂammatory properties
[4]. The chemical structure of garcinol is similar to that
of a series of naturally occurring phytochemicals such as2 Journal of Oncology
the chalcones, oglogifolins, and Guttiferones [5, 6]. Liq-
uid chromatography-tandem mass spectrometry method to
rapidly and sensitively detect the presence and quantify the
amount of garcinol present in a plant extract has now been
developed, paving the way to a rapid source of Garcinol and
hence a higher propensity of scientiﬁc investigations in this
area [7].
The chemistry of garcinol and its synthetic chalcone
analogs has been detailed in an earlier review [1]. In brief, as
compared to the native chalcones ﬂuorinated 2 hydroxychal-
cones have been reported to display increased antioxidative
potential and bioavailability, which was exhibited eﬀectively
in pancreatic (BXPC 3) and breast cancer (BT-20) cell lines
[8].
3.AntioxidativePropertiesof Garcinol
Oxidation and inﬂammation are considered to be under-
lying common causes of many chronic diseases including
atherosclerosis, Alzheimer’s’ disease, cancer as well as the
normal process of aging. Speciﬁcally, oxidative stress, the
imbalance between a system’s oxidative and the antioxidative
pathways, in favor of the former, is brought on primarily
by free radical species, resulting in cellular damage [9].
Antioxidants, by deﬁnition, inhibit oxidation by either
inhibiting pro-oxidants, thereby preventing the formation
of free radical species or by retarding the rate of reaction
of oxidative species with their biological targets, thereby
slowing down the free radical chain propagation [9]. Since
the free radical chain, if allowed to propagate, can follow
multiple pathways leading to a vast number of end products,
measurement of oxidative stress or a substance’s antioxida-
tive ability has always been considered to be precise, relative
to a speciﬁed biological condition or status, at best. Owing
to the large number of molecules aﬀected by free radicals,
leading to a varying population of end products, a sizable
array of independent assays have been put forward for the
measurement of oxidative stress or an agent’s antioxidative
capacity.
Theantioxidativeabilityofgarcinolhasbeeninvestigated
in in vitro and in vivo model systems [10]. Using a
hypoxanthine/xanthine oxidase system, garcinol was shown
to retard superoxide anion to nearly the same amount as
DL-alpha-tocopherol, an established anti-oxidant, while its
ability to quell hydroxyl radicals in the Fenton reaction
system was even better than that of alpha-tocopherol.
In addition, the authors also explored the antioxidative
power of garcinol in vivo using an indometacin induced
rat model for acute ulceration. Oral administration of
garcinol prevented acute ulceration in these rats, suggesting
its potential as an antiulcer drug [10]. In another study,
glutathione levels, known to be depleted due to oxidative
stress in the erythrocytes of streptozotocin-induced type-2
diabetic rats, were eﬀectively restored by oral administration
of an aqueous extract of the fruit of Garcinia indica [11].
This could be attributed to the anti-oxidant potential of
garcinol in the fruit extract. The protective role of garcinol
in neuronal survival and diﬀerentiation was investigated in
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Figure 1: Chemical structure of Garcinol [15].
cultured cortical progenitor cells. [12]. In another study,
antioxidative and neuroprotective properties of garcinol in
ratcorticalneuroncultureswasobserved.Thiswassuggested
to occur via prevention of nitric oxide NO accumulation in
lipopolysaccharide treated astrocytes [13].
The examples above help to establish the antioxidative
eﬀect of garcinol in vitro and in vivo model systems. In terms
of its structure, the phenolic hydroxyl groups coupled with
the β-diketone moiety in garcinol may, via formation of
resonance stabilized intermediates, help to prevent the free
radicalspeciesfrompropagatingandtherebylimitingfurther
oxidative-stress-related damage down the road.
4. Anticancer Properties of Garcinol
Cancer, the uncontrolled growth and spread of abnormal
cells,maybeinitiatedduetomultiplefactorsincludingexpo-
sure to carcinogens, repeated genetic damage, by oxidative
stress, chronic inﬂammation, or hormonal imbalance. Once
initiated, a cascade of reactions ensues, making it diﬃcult to
specify molecular targets for therapeutic advancements. As
such, most chemotherapeutic treatments suﬀer from adverse
toxic reactions leading to acute and delayed nausea, mouth
ulcerations, fatigue, nerve damage, blood clots, anemia, and
mild impairments [14]. Thus, it is important to develop
eﬀective preventative and/or therapeutic approaches, which
could potentially be both eﬀective against cancer cell growth
and relatively nontoxic. Recent evidence supports that
nonnutritive components in diet have therapeutic beneﬁts
attributable to their pleiotropic eﬀects including downreg-
ulation of survival signaling and simultaneous activation of
multiple death pathways in cancer cells.
A number of recent studies have examined the potential
of garcinol, a non-nutritive dietary component, against
diﬀerent cancer types (Table 1). In the process, a number
of possibilities that explain the underlying mechanism for
the chemopreventative and/or therapeutic performance of
garcinol have also arisen. These are summarized below.
4.1. Garcinol: Eﬀect on Inﬂammatory Pathways. The eﬀect
of dietary garcinol on the development of azoxymethane-Journal of Oncology 3
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Figure 2: Anticancer activity of Garcinol: mechanistic targets.
Table 1: List of studies investigating the role of Garcinol in diﬀerent cancer types.
Type of cancer Study type Experimental details Reference
Breast cancer
In vitro MDA, MB231, MCF-7 [16]
In vitro MCF-7, MDA-MB231 [17]
In vitro Primary culture, MCF-7 MDA-MB231,
AU 565 BT-483 [18]
Burkitt lymphoma In vitro TPA induced Ebvirus-EA activated raji
cells [19]
Colon cancer
In vitro HT-29, HCT-116 [16]
In vitro HT-29, HCT-116, ICE-6 [20]
In vitro HT-29 [21]
In vivo Azoxymethane induced colonic aberrant
crypt foci F344 rats [15]
Esophageal cancer In vitro SEG-1 [16]
Hepatocellular carcinoma
In vitro MH1C1-HEP G2 [22]
In vivo Hep3B [23]
In vitro Carcinogen induced liver cancer F344 rats [24]
HeLa cells In vitro HeLa core Histones-P300 HAT inhibition [25]
In vitro HeLa Histones [26]
Kidney cancer In vitro A293 (Human embryonic kinder
carcinoma) [16]
Leukemia
In vitro KBM-5 (chronic Leukemia) [16]
In vitro U937, K562, NB4, HL60 [27]
In vitro HL-60 [28]
In vitro HL-60 [15]
Lung cancer In vitro A-549 [29]
Medulloblastoma In vitro D a o y ,g r o w t hf a c t o r , [ 24]
Multiple myeloma In vitro U-266 [16]
Pancreatic cancer In vitro BxPC3 [30]
In vitro Panc-1, BxPC-3 [31]
Prostate cancer In vitro LNCaP, C4-2B, PC-3 [30]
In vitro PC-3 [16]
Tongue cancer In vivo 4-nitroquinoline 1-oxide induced oral
carcinogenesis in F344 rats [32]4 Journal of Oncology
(AOM-) induced colonic aberrant crypt foci (ACF), pre-
cursors for colon cancer, was investigated in male F344
rats [15]. Ingestion of 0.01% and 0.05% dietary garcinol
in rat models signiﬁcantly reduced the formation of ACF
in a dose-dependent manner, thus suggesting suppres-
sion in cancer development [15]. No adverse eﬀects were
reported with diets containing up to 0.05% by weight
of garcinol [15]. Additionally, garcinol consumption pro-
vided the added beneﬁt of increased liver glutathione S-
transferase (GST) and quinone reductase (QR) levels, both
detoxifying enzymes associated with cancer suppression
[15, 33].
Since carcinogenesis is often accompanied with increase
in oxidative stress, the authors also probed oxidative and
inﬂammatory pathways and investigated the response on
O2-, Nitric Oxide (NO), iNOS, and COX2 activity upon
treatment with garcinol in vitro. Garcinol inhibited O2-,
Nitric Oxide (NO), iNOS, and COX2 at a slightly greater
level than the green tea polyphenol, epigallocatechin gallate
(EGCG), an established plant antioxidant, in the cell lines
evaluated [15]. Taking the two together, it is possible that the
anticolon tumorigenesis activity of garcinol may in part be
due to modulation of iNOS and COX2 activities, although
mechanistic details need further elucidation [15].
The COX-2 expression in tongue lesions induced with 4-
nitroquinoline 1-oxide (4-NQO) in male F344 rats was also
decreased on feeding garcinol to these animals [32]. In this
study, dietary garcinol was administered either during the
period of exposure to the carcinogen or after the exposure
to carcinogen was complete. The animals fed the garcinol-
containing diet had signiﬁcantly decreased the incidence and
multiplicity of 4-NQO-induced tongue neoplasms and/or
preneoplasms as compared to the control diet under both
conditions. This shows the potential of garcinol both as a
preventative and therapeutic agent against tongue cancer. In
addition, the authors did not observe adverse eﬀects with
respect to survival rate, or any histological changes in the
liver or kidney that could be related to toxicity.
In another study, the mechanisms by which garcinol
modulates arachidonic acid metabolism and NO synthesis
in lipopolysaccharide- (LPS-) stimulated RAW264.7 murine
macrophages and in intestinal cell lines were examined [34].
Treatment with garcinol decreased the release of arachidonic
acid and its metabolites in the cell lines tested. Results
indicate that the suppression of arachidonic acid on treat-
ment with garcinol after the activation of LPS-stimulated
macrophagesmayoccurviainhibitionofcPLA2andERK1/2,
key factors in the release of arachidonic acid from membrane
phospholipids [34]. Conversely, garcinol treatment prior
to LPS-stimulation may lead to inhibition of the toll-
like receptors upstream of ERK 1/2 [34]. Additionally,
downregulation of NF-κB and COX-2 expressions, both
involved in the inﬂammatory response were also observed
[34].
Koeberle and coworkers showed that garcinol interferes
with 5-lipoxygenase and microsomal prostaglandin PGE2
synthase enzyme activity, both of which play crucial roles
in inﬂammation [29]. Further, garcinol inhibited synthesis
of PGE2 and 5-lipoxygenase in human neutrophils and
interleukin-stimulated human lung carcinoma cells [29].
The authors established that 5-lipoxygenase and certain
prostanoids are possible targets of garcinol, and may be of
potential pharmacological interest [29].
Prostaglandin E2 (PGE2) is produced by the action
Cox2 enzyme. It has been documented that aggressiveness
of pancreatic cancer increases with increase in the level of
PGE2 [35]. Targeting PGE2 can decrease inﬂammation and
proliferation and can reduce metastasis of pancreatic cancer
through various factors like MMP-2 and MMP-9 [36, 37].
In our laboratory, we have observed signiﬁcant reduction
in PGE2 expression levels in Cox 2-containing pancreatic
cancer cell line BXPC3 with treatment with garcinol.
Taken together, these studies demonstrate that inhibition
of inﬂammatory pathways via multiple but related targets
may play a pivotal role in garcinol’s response as an anti-
inﬂammatory and anticarcinogenic agent.
4.2. Garcinol: Eﬀect on Apoptotic Pathways. Another ap-
proach for halting cancerous growth involves targeting
apoptosis, programmed cell death of rapidly dividing cancer
cells. Garcinol exhibited greater induction of apoptosis than
curcumin in human leukemia HL-60 cells [28]. This was
mediated by release of cytochrome c into the cytoplasm of
the cell from the mitochondria allowing for the activation
of caspase-3. Apoptosis was also accompanied with down-
regulation of Bcl-2, an antiapoptotic protein and signiﬁcant
upregulation of Bad and Bax, established proapoptotic
proteins. The results suggest that apoptosis aﬀected by
garcinol is initiated by the release of cytochrome c into the
cytosol, followed by procaspase-9 processing, activation of
caspase-3 and caspase-2, degradation of PARP, and DNA
fragmentation [26–28].
Interestingly, when Hong and coworkers investigated the
eﬀect of garcinol on colon cancer and normal immortalized
intestinalcellline,garcinolshowedamuchhigherpotencyof
inhibition against the colon cancer cells as compared to the
normal cells. Greater growth inhibition was accompanied by
increaseinCaspase3activity,indicativeofanapoptoticpath-
way [30]. This diﬀerential response in activity against cancer
cells versus normal cells was also observed in breast cells [17,
20]. However, at exceptionally low doses (<1μM), garcinol
was reported to stimulate intestinal cell growth, possibly due
toproductionofhydrogenperoxideinthesystem,whichmay
not be eﬀectively quenched by the very low concentrations
of garcinol [20]. Thus, the beneﬁcial attributes of garcinol
are dose dependent. This phenomenon of induction of cell
growth at very low levels has been observed for other bioac-
tivecompoundsaswellincluding(−)epigallocatechingallate
[22].
Garcinol has also been shown to inhibit breast, prostrate
and pancreatic cancer cell growth by Induction of apoptosis
which was mediated by caspase-3 followed by downregula-
tion of the NFκBp a t h w a y[ 17, 30]. Chen et al., however,
documented that garcinol may exert its anticarcinogenic
eﬀects in nicotine-induced breast cancer cells by induction
of cell cycle arrest at the G0/G1 stage of mitosis [18]. In
addition,thisgroupshowedthatgarcinolachievedinhibitionJournal of Oncology 5
of breast cancer cell proliferation by suppressing nicotine-
induced nicotinic acetylcholine receptor (α9-nAChR) pro-
teinexpressionanddownregulatingtypeDcyclinsassociated
with mitotic cell cycle arrest [18].
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a cytokine known to elevate apoptosis via
death receptors DR4 and DR5, via their interaction with
Fas-associated domain (FADD), subsequently leading to
activation of the caspase-3 pathway. The aforementioned
cytochrome c/caspase 3 pathway can also be initiated by
TRAIL by mitochondrial cleavage and capase 9 activa-
tion [16]. On treatment with garcinol, various cancer cell
lines (colon, prostate, breast, kidney, leukemic, esophageal)
exhibited increased apoptosis via an induction of death
receptorsDR4andDR5[16].Thusitsactiondoesnotappear
to be speciﬁc to a particular cancer cell type. Moreover,
garcinol was also reported to suppress the expression of
prosurvival proteins survivin, bcl-2, XIAP, and cFLIP and
converselyampliﬁedproapoptoticpathwayssuchasinducing
cell membrane cleavage, increasing bax expression, and
subsequent release of cytochrome c [16].
Platelet-derived growth factor receptors (PDGFRs) are
implicated in medulloblastoma, the most common brain
tumor of childhood. A recent report detailed the cytotoxic
and antiapoptotic eﬀect of garcinol against brain tumor
cells (Daoy). The cytotoxicity, speciﬁcally against PDGFR-
regulated Daoy cells, was accompanied with a signiﬁcant S
phase cell cycle arrest, downregulation of cyclin A and E, and
activation of caspases [38].
4.3. Garcinol: Eﬀect on Epigenetic Control. Alteration in
genetic expression is yet another mechanism for the onset of
cancer. Hokaiwado et al. investigated changes of gene expres-
sion in livers of rats treated with carcinogens and tumor
promoters using a novel, three-dimensional microarray sys-
tem, customized to meet experimental requirements. Using
the customized microarray, garcinol was classiﬁed as chemo-
protective against liver cancer at a concentration of 0.05%
[24]. It was suggested that the likely mechanism of garcinol’s
anticarcinogenic activity involved the suppression of histone
acetyltransferases [26]. Histone acetylation is a mode of
chromatin remodeling, which enables gene transcription
there by altering cell growth [26]. Histone acetylation and
deacetylation is enabled by histone acetyltransferases (HATs)
and histone deacetyltransferases (HDACs) [26]. Dysfunction
of HAT can lead to cancers and therefore inhibitors of HAT
may be of use in cancer therapeutics [22, 25, 26]. Garcinol
inhibits HATs p300 and PCAF, thereby suppressing cell
proliferation, which leads to cancer repression [26]. Inter-
estingly, the speciﬁc inhibition of p300-HAT by a garcinol
derivative, LTK-14, resulted in a noncytotoxic inhibition of
HIV proliferation by preventing acetylation of HIV-infected
cells [39].
Micro-RNAs (miR) are a family of highly conserved
short RNA products (17–25 nucleotides) that control gene
expression at the posttranscriptional levels regulating diﬀer-
ent cancer types. Although the functional roles of all miRs
are not completely understood, they may act as oncogenes
and/or tumor suppressors regulating cellular diﬀerentiation,
proliferation, and apoptosis. We evaluated the eﬀect of
garcinol alone and in combination with gemcitabine on
microRNA proﬁle in human pancreatic cancer cell lines,
BxPC-3 and Panc-1. MicroRNA microarray proﬁle revealed
a variation in expression of several microRNAs. Interestingly
in our study, miR-21 (a signature of tumor aggressiveness)
was signiﬁcantly downregulated on treatment with garcinol
as compared to gemcitabine or the combination treatment
in gemcitabine-resistant cell line Panc-1, suggesting its role
in acquisition of chemoresistance. (unpublished data).
4.4. Garcinol: Eﬀect on Proliferation, Angiogenesis, and Metas-
tasis. Angiogenesisandmetastasisarehallmarksofadvanced
stages of carcinoma. Control at these stages is crucial
for patient prognosis. Garcinol has shown very promising
antiangiogenic and antimetastatic activities in vitro. Studies
fromourlaboratory,demonstratethatgarcinoldownregulat-
ed MMP-9, IL-8, PGE-2, and VEGF, markers of angiogenesis
and metastasis in pancreatic cancer cell lines, Panc 1 and
BxPC3. The eﬀects of garcinol were even more pronounced
inthePanc1cellline,carryingthek-rasmutation, implicated
in the majority of human pancreatic cancer patients [31].
In another study, the eﬀect of garcinol and other dietary
phytochemicals on cell proliferation and migration was
examined in rat liver bioassays and human hepatic cell
lines. Cell invasion assays using Matrigel analysis showed a
decrease in hepatocyte growth factor- induced cell invasion
of HepG2 and MH1C1 cells by garcinol. However, the eﬀects
were not statistically signiﬁcant and may need further inves-
tigation. According to recent study done on dysfunctional
P53 cell line Hep 3B Garcinol has shown induction of ROS
dependant apoptosis through death receptor, mitochondrial
and modulating GADD153 [22, 23].
We have also explored the possible synergistic eﬀects
between garcinol and other phytochemicals, including cur-
cumin as well as garcinol and currently available cancer
therapeutics,includinggemcitabine,inpancreaticcancercell
lines (unpublished data). In brief, using a combinatorial
design, our results showed that garcinol and curcumin in
concert show a greater decrease in cell growth via increased
induction of apoptosis in pancreatic cancer cells, Panc 1 and
BxPC3 than either agent alone.
In combination with the therapeutic, garcinol was seen
to synergistically sensitize pancreatic cancer cells to gemc-
itabine in vitro. Human pancreatic cancer cell lines, BxPC-
3 and Panc-1, harboring wild and mutant K-ras genotypes,
respectively, were treated with garcinol and gemcitabine
individually and in combination at diﬀerent doses and
times of incubation, to monitor growth inhibition and
degree of apoptotic cell death. The combination of garcinol
and gemcitabine showed a signiﬁcant reduction in cell
growth and increase in apoptosis as compared to respective
individual treatments. Further, garcinol in synergism with
gemcitabine induced its action by downregulating NF-κB,
VEGF, Il 8, MMP-9 and activating PARP cleavage. This
further highlights the potential of garcinol in combinatorial
therapeutic strategies.6 Journal of Oncology
Garcinol has also been shown to be involved in the
genetic modiﬁcation of Focal Adhesion Kinase (FAK), a
key player in the regulation of major processes in the
cell including cell proliferation, migration, and apoptosis
[21]. Garcinol was shown to downregulate FAK activity
by blocking its phosphorylation [21]. Subsequently, this
inhibition was shown to alter the Bcl-2/BAX ratio, further
leading to the activation of caspase-3 at a dose of 20μM[ 21].
5. Summary
Cancer, the uncontrolled growth and spread of abnormal
cells, results from the accumulation of numerous sequen-
tial mutations and alterations in nuclear and cytoplas-
mic molecules [40]. Cancer progression is considered to
involve three key steps: initiation, in which a normal
cell is transformed into an initiated or abnormal cell,
promotion, by which the initiated cell is converted into
a preneoplastic cell, and progression, the process whereby
t h ec e l l sb e c o m en e o p l a s t i c[ 41]. Cancer may be initiated
due to multiple factors including exposure to carcinogens,
repeated genetic damage by oxidative stress, chronic inﬂam-
mation, or hormonal imbalance. This followed by a cascade
of reactions, triggered by multiple signaling molecules
makes it diﬃcult to target a speciﬁc molecule responsible
for the disease and thereby retard progression. Thus, to
reduce cancer incidence and mortality rate and improve
the survival time of cancer patients, new techniques and
approaches must be developed to diagnose, prevent, and
treat preinvasive lesions. Most chemotherapeutic treatments
suﬀer from adverse toxic reactions leading to acute and
delayed nausea, mouth ulcerations, fatigue, nerve damage,
blood clots, anemia, and mild impairments [14]. Thus,
it is important to develop eﬀective preventative and/or
therapeutic approaches either in the form of single agents or
as combinations, which could potentially be both eﬀective
against cancer cell growth and relatively nontoxic. Recent
evidence supports that nonnutritive components in diet
have therapeutic beneﬁts attributable to their pleiotropic
eﬀects including downregulation of survival signaling and
simultaneousactivationofmultipledeathpathwaysincancer
cells.
Here, we have attempted to present the potential pre-
ventative and/or therapeutic role of garcinol, the active
component of Garcinia species against cancer progression.
Althoughstillpreliminaryinnature,recentevidencedemon-
strates that garcinol possesses multifunctional bioactivi-
ties including antimicrobial, anti-inﬂammatory, antioxidant,
apoptotic, antitumorigenic, and perhaps anti-neurodegener-
ative as well.
Inﬂammation and oxidative stress are the key culprits
implicated in numerous diseases, speciﬁcally in chronic
conditions such as cancer, cardiovascular, and Alzheimer’s
disease. In vitro and some in vivo studies have shown
that garcinol may inhibit these harmful chronic conditions
from possibly manifesting and propagating via multiple
mechanisms and sites of action. For instance, it behaves as
a potent antioxidant with appreciable free radical scavenging
activity, as also helping to avert inﬂammation, by suppress-
ing proinﬂammatory signaling molecules, prostaglandins,
leukotrienes and the signal transduction factor, NF-κB.
Garcinol’s inhibition of cancer growth of various types
including pancreatic, prostate, breast, leukemia, colon, and
its progression at diﬀerent stages, is especially intriguing.
Nonetheless, the full potential of this compound has yet
to be elucidated. Research-based evidence pointing to the
noncytotoxic nature against normal cells, combined with
potent proapoptotic behavior against cancerous cells, and its
antimicrobial eﬀects may be a testament to the traditional
use of the plant against multiple ailments. Forthcoming data
on its synergistic eﬀect with known drugs at subtherapeutic
doses may also open up new avenues for eﬃcient therapeutic
regimens without or with minimal adverse side eﬀects.
In addition, to date, no toxic eﬀects of Garcinol have
been reported, even when given orally upto 0.05% in diet.
However, further investigation to evaluate the range of its
therapeutic potential is required. Most of the advances in
the anticancer eﬀects of garcinol, although mechanistically
e x c i t i n g ,h a v eb e e na sar e s u l to fin vitro studies. These may
or may not be entirely reﬂected in an in vivo animal model
or a clinical situation. Thus the studies at present, although
potentially very useful, call out for an immense need for
carefully planned and executed studies in relevant animal
models of various cancer types to conﬁrm these ﬁndings.
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